Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Enzalutamide with Gemcitabine and Cisplatin in Bladder Cancer
NCT02300610Phase 1Completed
- Sponsor
- Moffitt Cancer Center
- Start
- Feb 2015
- Primary completion
- Aug 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of enzalutamide in bladder cancer (2 arms), sponsored by Moffitt Cancer Center. Primary endpoint: Recommended Dose of Enzalutamide up to 6 months. Started Feb 2015; status: completed.
02
Drugs
enzalutamide
03
Conditions
bladder cancer
Beyond the preview
Go deeper on NCT02300610.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02300610.